RE: RE: RE: RE: somethings brewing The advantage of MCC is:
1. It is not a live pathogen. Hence, there is no worry of continuous and/or secondary infections by the same agents and its muttants. Less hazard for handling.
2. it is related to a proven agent BCG which MD are already familiar with. Hence, much less learning curve in adopting the usage.
3. The added immuno-stimulant effect when used concommitantly with other chemo agent also gives it an additional purpose of utilization.
4. Even though the P3b recruitment was stopped, the continuation of trial on the ongoing subjects, if proven effective, could still provide us the impetus for application in BCG refractory cases later once Urocidin is approved for 1st line bladder cancer therapy.
Urocidin is a true winner if the P3a results can indeed be duplicated in a new trial. Let's hope BNC-Endo can come up with a sanctioned trial.
So far, I am sure there haev been some indications of its effectiveness from those early participants in the P3b trial. If we see Endo makes the effort to design and fight for a new trial, we can almost conclude the P3a results are believable and Urocidin is the real thing.